Several clinical parameters and biomarkers have been proposed as prognostic markers for stroke. However, it has not been clarified whether the risk factors affecting the prognosis of patients with recurrent and first-ever stroke are similar. In this study, we aimed to explore the relationship between soluble lectin-like oxidized low-density lipoprotein receptor 1 (sLOX-1) levels and the prediction of the functional outcome in patients with recurrent and first-ever stroke. A total of 266 patients with recurrent and first-ever stroke, who underwent follow-up for 3 months, were included in this study. Plasma samples were collected within 24 h after onset. The results showed that biomarkers for the prognosis of patients with recurrent stroke were different from that of those with first-ever stroke. sLOX-1 levels were correlated with modified Rankin Scale scores of patients with recurrent stroke alone (, ). sLOX-1 levels were also associated with an increased risk of unfavorable outcomes in patients with recurrent stroke with an adjusted odds ratio of 1.489 (95% confidence interval, 1.204–1.842, ). Combining the risk factors showed greater accuracy for prognosis, yielding a sensitivity of 93.2% and a specificity of 75%, with an area under the curve of 0.916, evaluated by the receiver operating characteristic curve. These findings suggest that the diagnosis and prognosis are different between patients with recurrent stroke and those with first-ever stroke, and sLOX-1 level is an independent prognostic marker in patients with recurrent stroke.

中文翻译：

---

sLOX-1：评估复发性缺血性中风预后的分子

一些临床参数和生物标志物已被提议作为中风的预后标志物。然而，尚未明确影响复发性和首次卒中患者预后的危险因素是否相似。在这项研究中，我们旨在探讨可溶性凝集素样氧化低密度脂蛋白受体 1 (sLOX-1) 水平与复发性和首次中风患者功能结果预测之间的关系。本研究共纳入 266 例复发性和首次中风患者，随访 3 个月。在发病后 24 小时内收集血浆样本。结果表明，复发性卒中患者预后的生物标志物与首次卒中患者不同。, ）。sLOX-1 水平还与复发性卒中患者不良结局的风险增加相关，调整后的优势比为 1.489（95% 置信区间，1.204-1.842，）。结合危险因素显示预后的准确性更高，灵敏度为 93.2%，特异性为 75%，曲线下面积为 0.916，由受试者工作特征曲线评估。这些研究结果表明，复发性卒中患者与首次卒中患者的诊断和预后不同，sLOX-1 水平是复发性卒中患者的独立预后标志物。